<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">METOCLOPRAMIDE HYDROCHLORIDE <img border="0" src="../images/pr.gif"/></span><br/>(met-oh-kloe-pra'mide)<br/><span class="topboxtradename">Clopra, </span><span class="topboxtradename">Emex <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Maxeran <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Maxolon, </span><span class="topboxtradename">Reglan<br/></span><b>Classifications:</b> <span class="classification">gastrointestinal agent</span>; <span class="classification">prokinetic agent (gi stimulant)</span><br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>5 mg, 10 mg tablets; 5 mg/5 mL solution; 5 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Potent central dopamine receptor antagonist. Structurally related to procainamide but has little antiarrhythmic or anesthetic
         activity. Exact mechanism of action not clear but appears to sensitize GI smooth muscle to effects of acetylcholine by direct
         action.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Increases resting tone of esophageal sphincter, and tone and amplitude of upper GI contractions. As a result, gastric emptying
         and intestinal transit are accelerated with little effect, if any, on gastric, biliary, or pancreatic secretions. Antiemetic
         action results from drug-induced elevation of CTZ threshold and enhanced gastric emptying. In diabetic gastroparesis, indicated
         by relief of anorexia, nausea, vomiting, persistent fullness after meals.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Management of diabetic gastric stasis (gastroparesis); to prevent nausea and vomiting associated with emetogenic cancer chemotherapy
         (e.g., cisplatin, dacarbazine); to facilitate intubation of small bowel; symptomatic treatment of gastroesophageal reflux.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Sensitivity or intolerance to metoclopramide; allergy to sulfiting agents; history of seizure disorders; concurrent use of
         drugs that can cause extrapyramidal symptoms; pheochromocytoma; mechanical GI obstruction or perforation; ileus; history of
         breast cancer; pregnancy (category B), lactation, children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>CHF, cardiac disease; sulfite hypersensitivity, asthma, hypokalemia, hypertension; depression; hepatic disease, infertility,
         methemoglobin reductase deficiency, Parkinson's disease, kidney dysfunction; GI hemorrhage; G6PD deficiency, procainamide
         hypersensitivity, seizure disorder, seizures, tardive dyskinesia; children; history of intermittent porphyria.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Gastroesophageal Reflux</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1015 mg q.i.d. a.c. and h.s.<br/><span class="rdage">Child:</span> <span class="rdroute">PO/IV/IM</span> 0.40.8 mg/kg/d in 4 divided doses<br/><br/><span class="indicationtitle">Diabetic Gastroparesis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 10 mg q.i.d. a.c. and h.s. for 28 wk<br/><span class="rdage">Geriatric:</span> <span class="rdroute">PO</span> 5 mg a.c and h.s.<br/><br/><span class="indicationtitle">Small-bowel Intubation, Radiologic Examination</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM/IV</span> 10 mg administered over 12 min<br/><span class="rdage">Child:</span> <span class="rdroute">IM/IV</span> <i> 0.1 mg/kg over 12 min; <i>614 y,</i> 2.55 mg over 12 min<br/><br/><span class="indicationtitle">Chemotherapy-induced Emesis</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">PO</span> 2 mg/kg 1 h before antineoplastic administration, may repeat q2h for 3 more doses if needed <span class="rdroute">IM/IV</span> 2 mg/kg 30 min before antineoplastic administration, may repeat q2h for 2 doses, then q3h for 3 doses if needed<br/></i></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give 30 min before meals and at bedtime.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li> 						Note: Verify correct IV concentration and rate of infusion for administration to infants or children with physician. 					</li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Doses of 10 mg or less may be given undiluted.  <span class="methodtype">IV Infusion:</span> Doses &gt;10 mg IV should be diluted in at least 50 mL of D5W, NS, D5/.45% NaCl, RL or other compatible solution.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give over 12 min.  <span class="methodtype">IV Infusion:</span> Give over 15 min. Note: Bags of metoclopramide should be protected from light during IV infusion (use of aluminum foil or
                  a thick cotton cover).  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span> <b>Ampicillin,</b> <b>calcium gluconate,</b> <b>cephalothin,</b> <b>chloramphenicol,</b> <b>cisplatin,</b> <b>erythromycin,</b> <b>floxacillin,</b> <b>fluorouracil,</b> <b>furosemide,</b> <b>methotrexate,</b> <b>penicillin G potassium,</b> <b>sodium bicarbonate,</b> <span class="classification">tetracyclines</span>. <span class="incompattype">Y-site:</span> <b>Allopurinol,</b> <b>amphotericin B cholesteryl complex,</b> <b>amsacrine,</b> <b>cefepime,</b> <b>doxorubicin liposome,</b> <b>furosemide,</b> <b>propofol.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Discard open ampules; do not store for future use.</li>
</ul>
<ul>
<li>Store at 15°30° C (59°86° F) in light-resistant bottle. Tablets are stable for 3 y; solutions
            and injections, for 5 y.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> <span class="speceff-common">Mild sedation, fatigue, restlessness,</span> agitation, headache, insomnia, disorientation, <span class="speceff-common">extrapyramidal symptoms</span> (acute dystonic type), neurologic malignant syndrome with injection. <span class="typehead">GI:</span> Nausea, constipation, <span class="speceff-common">diarrhea,</span> dry mouth, altered drug absorption. <span class="typehead">Skin:</span> Urticarial or maculopapular rash. <span class="typehead">Body as a Whole:</span> Glossal or periorbital edema. <span class="typehead">Hematologic:</span> Methemoglobinemia. <span class="typehead">Endocrine:</span> Galactorrhea, gynecomastia, amenorrhea, impotence. <span class="typehead">CV:</span> <span class="speceff-life">Hypertensive crisis</span> (rare). 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Metoclopramide may interfere with gonadorelin test by increasing <span class="alt">serum prolactin</span> levels.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Alcohol</b> and other <span class="classification">cns depressants</span> add to sedation; <span class="classification">anticholinergics</span>, <span class="classification">opiate analgesics</span> may antagonize effect on GI motility; <span class="classification">phenothiazines</span> may potentiate extrapyramidal symptoms; may decrease absorption of <b>acetaminophen,</b> <b>aspirin,</b> <b>atovaquone,</b> <b>diazepam,</b> <b>digoxin,</b> <b>lithium,</b> <b>tetracycline;</b> may antagonize the effects of <b>amantadine,</b> <b>bromocriptine,</b> <b>levodopa,</b> <b>pergolide,</b> <b>ropinirole,</b> <b>pramipexole;</b> may cause increase in extrapyramidal and dystonic reactions with <span class="classification">phenothiazines</span>, <span class="classification">thioxanthenes</span>, <b>droperidol,</b> <b>haloperidol,</b> <b>loxapine,</b> <b>metyrosine;</b> may prolong neuromuscular blocking effects of <b>succinylcholine.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Onset:</span> 3060 min PO; 1015 min IM; 13 min IV. <span class="typehead">Peak:</span> 12 h. <span class="typehead">Duration:</span> 13 h. <span class="typehead">Distribution:</span> Distributed to most body tissues including CNS; crosses placenta; distributed into breast milk. <span class="typehead">Metabolism:</span> Minimally metabolized in liver. <span class="typehead">Elimination:</span> 95% Excreted in urine, 5% in feces. <span class="typehead">Half-Life:</span> 2.56 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Report immediately the onset of restlessness, involuntary movements, facial grimacing, rigidity, or tremors. Extrapyramidal
            symptoms are most likely to occur in children, young adults, and the older adult and with high-dose treatment of vomiting
            associated with cancer chemotherapy. Symptoms can take months to regress.
         </li>
<li>Be aware that during early treatment period, serum aldosterone may be elevated; after prolonged administration periods, it
            returns to pretreatment level.
         </li>
<li>Lab tests: Periodic serum electrolyte.</li>
<li>Monitor for possible hypernatremia and hypokalemia (see Appendix F), especially if patient has CHF or cirrhosis.</li>
<li>Adverse reactions associated with increased serum prolactin concentration (galactorrhea, menstrual disorders, gynecomastia)
            usually disappear within a few weeks or months after drug treatment is stopped.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Avoid driving and other potentially hazardous activities for a few hours after drug administration.</li>
<li>Avoid alcohol and other CNS depressants.</li>
<li>Report S&amp;S of acute dystonia, such as trembling hands and facial grimacing (see Appendix F), immediately.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>